| Ms Ashley M Gruenhagen, PA-C | |
|
3600 Nw Samaritan Dr, Corvallis, OR 97330-5472 | |
| (541) 768-5111 | |
| Not Available |
| Full Name | Ms Ashley M Gruenhagen |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 3600 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134647142 | NPI | - | NPPES |
| 1134647142 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 4182-23 (Wisconsin) | Secondary |
| 363A00000X | Physician Assistant | PA217403 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
News Archive
Canada's ranking in international child health indexes would dramatically improve if measurements were standardized, according to a new study by researchers from the University of British Columbia, Dalhousie University, McGill University, the University of Calgary, and the Public Health Agency of Canada, working with the Canadian Perinatal Surveillance System and funded by the Canadian Institutes of Health Research (CIHR).
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.
Common diseases like allergy, diabetes and other immune diseases have increased dramatically in recent decades. This indicates that the environment may have a more important role than genes in explaining this increase.
In a paper published today in Nature's open access journal Scientific Reports, researchers at the University of Nevada, Reno report that male pseudoscorpions treated with the antibiotic tetracycline suffer significantly reduced sperm viability and pass this toxic effect on to their untreated sons. They suggest that a similar effect could occur in humans and other species.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Ashley M Gruenhagen, PA-C Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Ms Ashley M Gruenhagen, PA-C 3600 Nw Samaritan Dr, Corvallis, OR 97330-5472 Ph: (541) 768-5111 |
News Archive
Canada's ranking in international child health indexes would dramatically improve if measurements were standardized, according to a new study by researchers from the University of British Columbia, Dalhousie University, McGill University, the University of Calgary, and the Public Health Agency of Canada, working with the Canadian Perinatal Surveillance System and funded by the Canadian Institutes of Health Research (CIHR).
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that its U.S. licensee for PENNSAID (diclofenac sodium topical solution) 1.5% w/w and PENNSAID 2% (diclofenac sodium topical solution) 2% w/w, Mallinckrodt has advised that the U.S. Food and Drug Administration has accepted for filing and review the New Drug Application for PENNSAID 2% submitted by Mallinckrodt on August 7, 2013.
Common diseases like allergy, diabetes and other immune diseases have increased dramatically in recent decades. This indicates that the environment may have a more important role than genes in explaining this increase.
In a paper published today in Nature's open access journal Scientific Reports, researchers at the University of Nevada, Reno report that male pseudoscorpions treated with the antibiotic tetracycline suffer significantly reduced sperm viability and pass this toxic effect on to their untreated sons. They suggest that a similar effect could occur in humans and other species.
› Verified 6 days ago
Michael J Mccusker, P. A.-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 530 Nw 27th St, Corvallis, OR 97330 Phone: 541-766-6611 Fax: 541-766-6186 | |
Ms. Stacie Marie Fulcher, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 441 Nw Elks Dr Ste 100, Corvallis, OR 97330 Phone: 541-768-4950 | |
Gregory Miller, Physician Assistant Medicare: Medicare Enrolled Practice Location: 530 Nw 27th St, Corvallis, OR 97330 Phone: 541-766-6835 | |
Taylor Frank, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3640 Nw Samaritan Dr Ste 120, Corvallis, OR 97330 Phone: 541-768-5223 | |
John Narciso Navarro, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 | |
Beth Anne Rathbun, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 444 Nw Elks Dr, Corvallis, OR 97330 Phone: 541-754-1287 | |
Ms. Annemarie Boyd, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |